- Axonics Modulation Technologies Inc (NASDAQ: AXNX) has acquired UK-based Contura and its lead product Bulkamid, a urethral bulking agent used to treat female stress urinary incontinence.
- The transaction includes a total consideration of $200 million in cash and stock, along with a potential future milestone of $35 million.
- Bulkamid is a homogenous non-particulate hydrogel injected into the urethral wall in a minimally invasive office or outpatient facility procedure for restoring the urethra’s natural closing pressure.
- The hydrogel secured CE Mark approval in 2003 and the FDA approval last year.
- Price Action: AXNX shares are 1.34% higher at $51.50 in the premarket session on the last check Friday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
